Toll-like receptors, endogenous ligands, and systemic autoimmune disease

被引:320
作者
Rifkin, IR
Leadbetter, EA
Busconi, L
Viglianti, G
Marshak-Rothstein, A
机构
[1] Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Dept Med, Renal Sect, Boston, MA 02118 USA
[3] Harvard Univ, Sch Med, BWH, Div Rheumatol Allergy & Immunol, Boston, MA USA
关键词
D O I
10.1111/j.0105-2896.2005.00239.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The critical role of Toll-like receptors (TLRs) as mediators of pathogen recognition by the innate immune system is now firmly established. Such recognition results in the initiation of an inflammatory immune response and subsequent instruction of the adaptive immune system, both of which are designed to rid the host of the invading pathogen. More controversial is the potential role of TLRs in the recognition of endogenous ligands and what effect this might have on the consequent development of autoimmune or other chronic sterile inflammatory disorders. An increasing number of studies implicate TLRs as being involved in the immune response to self-molecules that have in some way been altered from their native state or accumulate in non-physiologic sites or amounts, although questions have been raised about possible contaminants in certain of these studies. In this review, we discuss the evidence for endogenous ligand-TLR interactions with particular emphasis on mammalian chromatin, systemic lupus erythematosus, and atherosclerosis. Overall, the data support the general concept of a role for TLRs in the recognition of endogenous ligands. However, the precise details of the interactions and the extent to which they may contribute to the pathogenesis of human disease remain to be clarified.
引用
收藏
页码:27 / 42
页数:16
相关论文
共 146 条
[1]   Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function [J].
Adachi, O ;
Kawai, T ;
Takeda, K ;
Matsumoto, M ;
Tsutsui, H ;
Sakagami, M ;
Nakanishi, K ;
Akira, S .
IMMUNITY, 1998, 9 (01) :143-150
[2]  
Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO
[3]  
2-U
[4]   Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 [J].
Alexopoulou, L ;
Holt, AC ;
Medzhitov, R ;
Flavell, RA .
NATURE, 2001, 413 (6857) :732-738
[5]   Association of the toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events [J].
Ameziane, N ;
Beillat, T ;
Verpillat, P ;
Chollet-Martin, S ;
Aumont, MC ;
Seknadji, P ;
Lamotte, M ;
Lebret, D ;
Ollivier, V ;
de Prost, D .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (12) :E61-E64
[6]   Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice [J].
Anders, HJ ;
Vielhauer, V ;
Eis, V ;
Linde, Y ;
Kretzler, M ;
de Lema, GP ;
Strutz, F ;
Bauer, S ;
Rutz, M ;
Wagner, H ;
Gröne, HJ ;
Schlbndorff, D .
FASEB JOURNAL, 2004, 18 (01) :534-+
[7]   Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease [J].
Aprahamian, T ;
Rifkin, I ;
Bonegio, A ;
Hugel, B ;
Freyssinet, JM ;
Sato, K ;
Castellot, JJ ;
Walsh, K .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (08) :1121-1131
[8]  
Batteux F, 1999, EUR CYTOKINE NETW, V10, P509
[9]   Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition [J].
Bauer, S ;
Kirschning, CJ ;
Häcker, H ;
Redecke, V ;
Hausmann, S ;
Akira, S ;
Wagner, H ;
Lipford, GB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (16) :9237-9242
[10]  
Bausinger H, 2002, EUR J IMMUNOL, V32, P3708, DOI 10.1002/1521-4141(200212)32:12<3708::AID-IMMU3708>3.0.CO